William Blair Analysts Raise Earnings Estimates for Hologic

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair upped their Q2 2025 EPS estimates for Hologic in a research report issued on Monday, November 11th. William Blair analyst A. Brackmann now forecasts that the medical equipment provider will post earnings of $1.07 per share for the quarter, up from their prior estimate of $1.05. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS.

Several other equities analysts have also recently issued reports on the stock. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Stephens reiterated an “overweight” rating and set a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday. Finally, UBS Group upped their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Trading Up 1.4 %

NASDAQ:HOLX opened at $78.60 on Thursday. Hologic has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock’s 50 day simple moving average is $80.71 and its 200-day simple moving average is $78.23. The firm has a market cap of $18.26 billion, a P/E ratio of 23.60, a PEG ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $0.89 earnings per share.

Hedge Funds Weigh In On Hologic

Several hedge funds have recently added to or reduced their stakes in the business. State Street Corp grew its position in shares of Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after purchasing an additional 81,057 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after buying an additional 2,753,016 shares during the last quarter. FMR LLC grew its holdings in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after buying an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after acquiring an additional 18,774 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Hologic by 21.6% in the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after acquiring an additional 450,190 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.